Academic Collaborators

MaxCyte's first therapeutic under collaborative development for eventual outlicensing is a cell therapy for the treatment of chronic lymphocytic leukemia (CLL) and is currently in a Phase IIa trial led by Dr. Malcolm Brenner, Director, Center for Cell and Gene Therapy at Baylor College of Medicine and The Methodist Hospital, Houston. Human proof of concept for this vaccine approach was previously established in two Phase I studies by the University of California San Diego and Baylor. In these earlier studies, the vaccine showed signs of efficacy, but was stalled due to safety and production issues. After producing a cell product using MaxCyte's approach, human trials began last year. Preliminary results from the current Phase IIa program at Baylor have established consistency in product manufacturing and quality and no safety concerns have been reported. Based upon promising early immune and clinical responses, the Phase IIa trial has been extended to refine dose and protocol with completion scheduled for 2008/2009.
  • Case Study: Overcoming Obstacles to develop a Cancer Immunotherapeutic (PDF) [Click Here]

Baylor College of Medicine Stanford University University of Pennsylvania Duke University St. Jude's Children's Research Hospital